Featured Trial
Clinical Trial Goal
To find out if an engineered donor graft is safe and works well to treat blood cancer for people getting an allogeneic BMT
You may be able to join this trial if you:
- Are 18 – 65 years old
- Have one of the following diseases:
- Acute lymphocytic leukemia (ALL) that has gotten better after treatment (complete remission)
- Acute myeloid leukemia (AML) in complete remission
- Mixed phenotype leukemia in complete remission
- Myelodysplastic syndrome (MDS) that doctors consider high risk
- Are able to get an allogeneic BMT with intense (myeloablative) chemotherapy (chemo). Your doctor can tell you this
- Have not had an allogeneic BMT
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Your donor’s blood-forming cells will be collected and treated in a lab. Doctors think that treating them in this way will help the donated cells grow and lower the chances of graft-versus-host disease (GVHD).
First, you’ll be treated with standard myeloablative chemo to prepare your body for transplant.
On transplant day, the treated blood-forming cells from your donor will be given to you as an intravenous (IV) infusion.
You’ll also get standard treatment to prevent GVHD.
You’ll have biopsies to see how well treatment is working. After treatment, the clinical trial doctors will check your health for 1 year.
The Food and Drug Administration (FDA) not yet approved this type of engineered donor graft in an allogeneic BMT to treat blood cancer.
First, you’ll be treated with standard myeloablative chemo to prepare your body for transplant.
On transplant day, the treated blood-forming cells from your donor will be given to you as an intravenous (IV) infusion.
You’ll also get standard treatment to prevent GVHD.
You’ll have biopsies to see how well treatment is working. After treatment, the clinical trial doctors will check your health for 1 year.
The Food and Drug Administration (FDA) not yet approved this type of engineered donor graft in an allogeneic BMT to treat blood cancer.
Contacts
Tamara Zharkevich, MD PhD, 1-530-414-9743, info@orcabiosystems.com
James S McClellan, MD, PhD, 1-530-414-9743, info@orcabiosystems.com
Locations
Sponsors
lead: Orca Biosystems, Inc.
